Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M
Source: SeekingAlpha
2026-03-05 07:11:11 ET
More on Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
- Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Lexicon Pharma spikes after insider buy
- Lexicon Pharmaceuticals prices $94.6M share offering
- Seeking Alpha’s Quant Rating on Lexicon Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M
Lexicon Pharmaceuticals Inc.
NASDAQ: LXRX
LXRX Trading
-5.44% G/L:
$1.65 Last:
1,733,639 Volume:
$1.72 Open:
LXRX Latest News
March 05, 2026 06:59:00 am
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
March 03, 2026 04:01:00 pm
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
LXRX Stock Data
$557,345,360
216,958,960
0.2%
137
N/A
Biotechnology & Life Sciences
Healthcare
US
The Woodlands
